{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75.1","upperLimit":"96.1","value":"89.8"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"71.5","upperLimit":"94.4","value":"87.0"}]}],"title":"9 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.2","upperLimit":"88.3","value":"77.8"}]}],"title":"12 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Progression/death event-free rates were estimated by Kaplan-Meier method with 95% confidence intervals (CIs) estimated using Greenwood's formula","dispersionType":"95% Confidence Interval","groups":[{"description":"Zanubrutinib 160 mg orally twice daily with or without food until progressive disease or intolerable toxicity","id":"OG000","title":"Zanubrutinib"}],"paramType":"NUMBER","populationDescription":"Efficacy Analysis Set includes participants with confirmed Waldenström's macroglobulinemia based on central pathologic review among those who received at least one dose of study drug and with a baseline IgM (or M-protein) ≥ 5 g/L","reportingStatus":"POSTED","timeFrame":"Up to approximately 1 year and 9 months","title":"PFS: Event-free Rate","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}